Targeting the cell cycle for cancer therapy

Most if not all neoplasias show a directly or indirectly deregulated cell cycle. Targeting its regulatory molecules, the cyclin-dependent kinases, as a therapeutic mode to develop new anticancer drugs, is being currently explored in both academia and pharmaceutical companies. The development of new compounds is being focused on the many features of the cell cycle with promising preclinical data in most fields. Moreover, a few compounds have entered clinical trials with excellent results maintaining the high hopes. Thus, although too early to provide a cell cycle target based new commercial drug, there is no doubt that it will be an excellent source of new anticancer compounds.

[1]  L Meijer,et al.  Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. , 1999, Pharmacology & therapeutics.

[2]  K. Vousden,et al.  p53 in signaling checkpoint arrest or apoptosis. , 1996, Current opinion in genetics & development.

[3]  C. Fisher,et al.  Antisense phosphorothioate oligonucleotides specifically down‐regulate cdc25B causing S‐phase delay and persistent antiproliferative effects , 1998, International journal of cancer.

[4]  A. Senderowicz.  Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies , 2001, Leukemia.

[5]  G. Draetta,et al.  Cdc25 protein phosphatases in cell proliferation. , 1997, Biochimica et biophysica acta.

[6]  W. Kaelin,et al.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Pines,et al.  Cyclins and cyclin-dependent kinases: a biochemical view. , 1995, The Biochemical journal.

[8]  E. Sausville,et al.  Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication* , 2000, The Journal of Biological Chemistry.

[9]  E. Vokes,et al.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. van den Heuvel,et al.  Distinct roles for cyclin-dependent kinases in cell cycle control. , 1993, Science.

[11]  P. Maslak,et al.  Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Roth,et al.  Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. , 1995, Cancer research.

[13]  Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 , 1997, Current Biology.

[14]  D. Schrump,et al.  Inhibition of lung cancer proliferation by antisense cyclin D. , 1996, Cancer gene therapy.

[15]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[16]  J. Eckstein.  Cdc25 as a Potential Target of Anticancer Agents , 2000, Investigational New Drugs.

[17]  R. Fåhraeus,et al.  Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide from p16CDKN2/INK4A , 1996, Current Biology.

[18]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[19]  S. Mani,et al.  Cyclin-dependent kinase inhibitors: novel anticancer agents , 2000, Expert opinion on investigational drugs.

[20]  A. Levine,et al.  p53 and E2F-1 cooperate to mediate apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Shuford,et al.  Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. , 1996, Oncogene.

[22]  N. Pavletich.  Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. , 1999, Journal of molecular biology.

[23]  J. Yuan,et al.  Polo-like kinase, a novel marker for cellular proliferation. , 1997, The American journal of pathology.

[24]  P. Nurse.  Checkpoint Pathways Come of Age , 1997, Cell.

[25]  L. Hengst,et al.  Inhibitors of the Cip/Kip family. , 1998, Current topics in microbiology and immunology.

[26]  K. Griebenow,et al.  Primary processes in isolated photosynthetic bacterial reaction centres from Chloroflexus aurantiacus studied by picosecond fluorescence spectroscopy , 1991 .

[27]  M. Korc,et al.  Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. , 1998, The Journal of clinical investigation.

[28]  Kenneth Cowan,et al.  A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells , 1997, Oncogene.

[29]  D. Beach,et al.  Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cyclins , 1991, Cell.

[30]  S. Srivastava,et al.  Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells , 1998, Oncogene.

[31]  B. Brinkley,et al.  The centrosome-associated Aurora/Ipl-like kinase family. , 2000, Current topics in developmental biology.

[32]  K. McMasters,et al.  Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  L. Meijer,et al.  Cyclin dependent kinase inhibitors , 2003 .

[34]  R. Fåhraeus,et al.  Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. , 1996, Current Biology.

[35]  H. Lane,et al.  The family of polo-like kinases. , 1996, Progress in cell cycle research.

[36]  S. Steinberg,et al.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Broggini,et al.  p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. , 1997, Cancer research.

[38]  W. Yung,et al.  Overexpression of E2F‐1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo , 1998, Nature Medicine.

[39]  G. Draetta.  Mammalian G1 cyclins. , 1994, Current opinion in cell biology.

[40]  P. Crespo,et al.  Ras proteins in the control of the cell cycle and cell differentiation , 2000, Cellular and Molecular Life Sciences CMLS.

[41]  G. Hannon,et al.  The INK4 family of CDK inhibitors. , 1998, Current topics in microbiology and immunology.

[42]  Roger Brent,et al.  Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2 , 1996, Nature.

[43]  B. Amati,et al.  Myc and the cell cycle. , 1998, Frontiers in bioscience : a journal and virtual library.

[44]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[45]  T. Liu,et al.  Adenovirus‐mediated E2F‐1 gene transfer efficiently induces apoptosis in melanoma cells , 1999, Cancer.

[46]  K L Gould,et al.  Regulating the onset of mitosis. , 1999, Current opinion in cell biology.

[47]  K. Helin,et al.  The E2F transcription factors: key regulators of cell proliferation. , 2000, Biochimica et biophysica acta.

[48]  M. Malumbres,et al.  RAS pathways to cell cycle control and cell transformation. , 1998, Frontiers in bioscience : a journal and virtual library.

[49]  D. Lane,et al.  Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. , 2000, Current medicinal chemistry.

[50]  S. Henikoff.  Heterochromatin function in complex genomes. , 2000, Biochimica et biophysica acta.

[51]  X. Graña,et al.  Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth , 1998, Oncogene.

[52]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[53]  W. Muller,et al.  Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity , 1999, Oncogene.

[54]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[55]  E. Sausville,et al.  Preclinical and clinical development of cyclin-dependent kinase modulators. , 2000, Journal of the National Cancer Institute.

[56]  B. Posner,et al.  Arrest at the G2/M transition of the cell cycle by protein‐tyrosine phosphatase inhibition: Studies on a neuronal and a glial cell line , 1995, Journal of cellular biochemistry.

[57]  P. Clarke,et al.  Cyclin-Dependent Kinases: CAK-handed kinase activation , 1995, Current Biology.

[58]  H. Katayama,et al.  Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. , 1998, Cancer research.

[59]  L. Cerutti,et al.  Controlling the end of the cell cycle. , 2000, Current opinion in genetics & development.

[60]  L Meijer,et al.  Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. , 1999, Pharmacology & therapeutics.